奕瑞科技(688301.SH):6名股東共完成減持4.79%股份
格隆匯3月22日丨奕瑞科技(688301.SH)公佈,公司近期收到蘇州北極光、上海辰岱、辰德春華、蘇州辰知德分別出具的《關於股份減持結果的吿知函》;天津紅杉、北京紅杉出具的《關於奕瑞科技股份減持計劃實施情況的吿知函》。
截至2022年3月21日,蘇州北極光累計減持82.91萬股,佔公司股份總數的1.14%;上海辰岱、辰德春華、蘇州辰知德累計減持252.7425萬股,佔公司股份總數的3.48%;天津紅杉、北京紅杉累計減持公司股票12萬股,佔公司股份總數的0.17%。該次減持計劃實施減持時間屆滿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.